Laurus Labs Q4 results: Net profit more than triples to ₹234 crore; dividend declared – check other key details

Laurus Labs, the Hyderabad-based active pharmaceutical ingredients maker, on Thursday, April 24, reported consolidated net profit of ₹234 crore in quarter ended March 2025, marking an increase of 3.09 times from ₹75.61 crore in the same period last year. The sharp jump in profit in fourth quarter of financial year 2025 came on the back of improvement in operating profit margin of the company.

Laurus Labs operating profit also known as earnings before interest, taxes, depreciation, and amortisation (EBITDA) improved by 783 basis points to 24.71% as against 16.77% in the year-ago period. The company's EBITDA came in at ₹420 crore, up 74% from ₹241 crore the corresponding period last financial year.

The company’s board approved a dividend payout of 80 pasie per share.

"The board of Directors approved the payment of 2nd Interim Dividend of ₹0.80/- (40%) per equity share of ₹2/- each, for the Financial Year 2024-25," the company said in a regulatory filing.

Laurus Labs revenue from operations advanced 20% to ₹1,720 crore in Q4 from ₹1,440 crore in the same period last year.

For financial year 2024-25, Laurus Labs net profit jumped 123% to ₹358 crore as against ₹160.55 crore in financial year 2023-24.

"During the year ended March 31, 2025, the Company allotted 286,633 equity shares of~ 2/- each, consequent to the exercise of the stock options by the employees of the Company under the Employee Stock Option Scheme," Laurus Labs said.

Laurus Labs shares ended 0.51% lower at ₹647 after its earnings announcement.